Objectives: Determine the frequency of individual cytological categories of findings of tumor formations in the thyroid gland. Determine the reliability of cytological diagnosis according to the Bethesda categories in relation to pathohistological diagnoses in thyroid tumors. Determine the number of cytological findings of benign follicular formations and tumors with cytological malignant characteristics in relation to the pathohistological findings. Determine the characteristics of the tumor according to gender and age. Study Design: A cross-sectional study with historical data. Participans and methods: The study includes participans in whom a cytological puncture of ultrasound-verified tumor changes in the thyroid gland was performed, and for whom subsequent pathohistological verification was performed. The research was conducted between January 1, 2017 to Decembre 31, 2021. The records of cytological and pathohistological findings from the Clinical Institute for Clinical Cytology and the Clinical Institute for Pathology and Forensic Medicine will be used to analyze the above data. Results: Cytologically, 43,1 % of the subjects were diagnosed with a tumor indicating a follicular or Hurthle's tumor, and 27 % of the participants with a cytological suspicion of a malignant tumor. An undoubted cytological diagnosis of malignant tumor was made in 25 % of the subjects. According to the pathohistological diagnosis, the majority are papillary carcinomas, accounting for 44,2 % of cases. The remaining cases include follicular and Hurthle cell tumors 25 %, colloid cystic stroma 20 %, medullary carcinoma 3 %, follicular carcinoma 3 %, anaplastic carcinoma 2 %, and Hurthle cell carcinoma and NIFTP in 0,4 % of cases. Conclusion: The research showed that the distribution of cytological Bethesda categories T3, T4, T5, T6 is significantly different in relation to PHD findings. Cytological categories malignant and suspicious for malignancy are significantly more often associated with the pathohistological diagnosis of papillary carcinoma.